Haemonetics (HAE)
NYSE:HAE
Want to see HAE full AI Analyst Report?
Total Valuation
Haemonetics has a market cap or net worth of $2.62B. The enterprise value is $3.60B.
Market Cap$2.62B
Enterprise Value$3.60B
Share Statistics
Haemonetics has 46,471,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,471,350
Owned by Insiders1.39%
Owned by Institutions18.80%
Financial Efficiency
Haemonetics’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.66%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)8.66%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee364.79K
Profits Per Employee26.61K
Employee Count3,657
Asset Turnover0.56
Inventory Turnover1.93
Valuation Ratios
The current PE Ratio of Haemonetics is ―. Haemonetics’s PEG ratio is -0.69.
PE Ratio―
PS Ratio1.91
PB Ratio3.20
Price to Fair Value3.20
Price to FCF9.79
Price to Operating Cash Flow8.87
PEG Ratio-0.69
Income Statement
In the last 12 months, Haemonetics had revenue of 1.33B and earned 97.31M in profits. Earnings per share was 2.05.
Revenue1.33B
Gross Profit743.59M
Operating Income241.40M
Pretax Income128.03M
Net Income97.31M
EBITDA397.12M
Earnings Per Share (EPS)2.05
Cash Flow
In the last 12 months, operating cash flow was 293.22M and capital expenditures -32.78M, giving a free cash flow of 260.44M billion.
Operating Cash Flow293.22M
Free Cash Flow260.44M
Free Cash Flow per Share5.60
Dividends & Yields
Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.57
52-Week Price Change-18.84%
50-Day Moving Average59.89
200-Day Moving Average64.34
Relative Strength Index (RSI)57.41
Average Volume (3m)701.61K
Important Dates
Haemonetics upcoming earnings date is Aug 11, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Haemonetics as a current ratio of 2.95, with Debt / Equity ratio of 153.78%
Current Ratio2.95
Quick Ratio1.87
Debt to Market Cap0.48
Net Debt to EBITDA2.47
Interest Coverage Ratio8.41
Taxes
In the past 12 months, Haemonetics has paid 30.72M in taxes.
Income Tax30.72M
Effective Tax Rate0.24
Enterprise Valuation
Haemonetics EV to EBITDA ratio is 8.89, with an EV/FCF ratio of 13.55.
EV to Sales2.65
EV to EBITDA8.89
EV to Free Cash Flow13.55
EV to Operating Cash Flow12.03
Balance Sheet
Haemonetics has $245.44M in cash and marketable securities with $1.22B in debt, giving a net cash position of -$979.14M billion.
Cash & Marketable Securities$245.44M
Total Debt$1.22B
Net Cash-$979.14M
Net Cash Per Share-$21.07
Tangible Book Value Per Share-$6.52
Margins
Gross margin is 57.34%, with operating margin of 18.10%, and net profit margin of 7.29%.
Gross Margin57.34%
Operating Margin18.10%
Pretax Margin9.60%
Net Profit Margin7.29%
EBITDA Margin29.77%
EBIT Margin18.10%
Analyst Forecast
The average price target for Haemonetics is $72.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$72.67
Price Target Upside17.93% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast-1.97%
EPS Growth Forecast-38.95%